Company news
Genedrive PLC news in 2024
Genedrive PLC's news releases, calls and decks from 2024, newest first.
Genedrive® CYP2C19-ID Kit performance published
December 27, 2024
Grant of Options
December 20, 2024
Posting of annual report and notice of AGM
December 5, 2024
Block listing returns
November 29, 2024
NIHR and OLS Funding Package
November 21, 2024
Department for Business and Trade feature
November 5, 2024
Scottish Health Technology Group publications
November 4, 2024
Director Declaration
October 21, 2024
Director/PDMR Shareholding
August 15, 2024
First UK commercial sales of the CYP2C19-ID Kit
August 12, 2024
Directorate Change
August 6, 2024
NICE recommends CYP2C19-ID Kit in final guidance
July 31, 2024
Breakthrough Device Designation from the U.S. FDA
July 15, 2024
Short extension to NICE publication date
June 27, 2024
Result of Open Offer and REX Offer
May 30, 2024
Initial orders of the Genedrive MT-RNR1 Products
May 24, 2024
Key CYP2C19-ID test performance milestone achieved
May 21, 2024
Amendment to Open Offer timetable
May 15, 2024
Completion of placing
May 10, 2024
Proposed REX Retail Offer
May 9, 2024
Clinical Trial Agreement
April 24, 2024
NICE recommends the Genedrive CYP2C19-ID Kit
April 3, 2024
Half-year Report
March 28, 2024
Investor presentation
March 26, 2024
Receipt of R&D tax credit
March 15, 2024
NICE Early Value Assessment update
February 19, 2024
Total Voting Rights
February 2, 2024
Equity Prepayment Facility drawdown
January 2, 2024